Table 1.
Sample description.
| Before the pandemic | In the last 4 weeks (during pandemic) | ||||||
|---|---|---|---|---|---|---|---|
| User | User | Non-user | P a | ||||
| n | (%) | n | (%) | n | (%) | ||
| Sample size | 1,332 | (96.9)b | 641 | (46.6)b | 734 | (53.4)b | |
| Age in years (range) | 26.6 | (18-67) | 26.6 | (18-62) | 26.4 | (18-67) | 0.574 |
| Gender | 0.417 | ||||||
| Female | 471 | (35.4) | 220 | (34.3) | 274 | (37.3) | |
| Male | 811 | (60.9) | 392 | (61.2) | 437 | (59.5) | |
| Non-binary | 33 | (2.5) | 20 | (3.1) | 15 | (2.0) | |
| Education (at time of survey) | 0.586 | ||||||
| University degree | 612 | (46.0) | 297 | (46.3) | 334 | (41.9) | |
| Secondary school degree | 561 | (42.1) | 273 | (42.6) | 308 | (45.6) | |
| Vocational training | 111 | (8.3) | 54 | (8.4) | 59 | (8.0) | |
| No degree | 48 | (3.6) | 17 | (2.7) | 33 | (4.5) | |
| Work situation (before COVID-19 pandemic) | 0.050 | ||||||
| Employed | 531 | (39.8) | 276 | (43.1) | 272 | (37.1) | |
| Freelancer/Self-employed | 271 | (20.4) | 126 | (19.7) | 150 | (20.4) | |
| Temporary employment | 83 | (6.2) | 34 | (5.3) | 50 | (6.8) | |
| Seeking work | 168 | (12.6) | 67 | (10.5) | 105 | (14.3) | |
| Unpaid domestic work/ Parental leave | 20 | (1.5) | 13 | (2.0) | 9 | (1.3) | |
| Student employment | 231 | (17.3) | 116 | (18.1) | 129 | (17.6) | |
| Retired | 15 | (1.1) | 5 | (0.8) | 10 | (1.4) | |
| Household size | 0.381 | ||||||
| No other person | 179 | (13.4) | 97 | (15.1) | 91 | (12.4) | |
| 1 other person | 226 | (17.0) | 120 | (18.7) | 116 | (15.8) | |
| ≥2 other persons | 927 | (69.6) | 424 | (66.2) | 527 | (71.8) | |
| Children living in household | 0.100 | ||||||
| None | 1,060 | (79.6) | 501 | (78.2) | 598 | (81.5) | |
| 1 child | 147 | (11.0) | 70 | (10.9) | 78 | (10.6) | |
| ≥2 children | 123 | (9.3) | 69 | (10.8) | 57 | (7.8) | |
| Psychedelic substance use | |||||||
| LSD | 1,147 | (86.1) | 445 | (69.4) | |||
| Psilocybin | 739 | (55.5) | 205 | (32.0) | |||
| 2C-B | 324 | (24.3) | 85 | (13.3) | |||
| DMT | 307 | (23.0) | 76 | (11.9) | |||
| New Psychedelics | 248 | (18.6) | 66 | (10.3) | |||
| Mescaline | 156 | (11.5) | 32 | (5.0) | |||
| Ayahuasca | 117 | (8.8) | 21 | (3.3) | |||
| 5-MeO-DMT | 63 | (4.7) | 13 | (2.0) | |||
| Other | 24 | (1.8) | 6 | (0.9) | |||
| Other substances used in 2019 or 2020 | 0.276 | ||||||
| Alcohol | 1,245 | (93.5) | 594 | (92.7) | 691 | (94.1) | |
| Cannabis | 1,244 | (93.4) | 592 | (92.4) | 691 | (94.1) | |
| Nicotine | 958 | (71.9) | 445 | (69.4) | 535 | (72.9) | |
| MDMA | 798 | (59.9) | 386 | (60.2) | 427 | (58.2) | |
| Cocaine | 727 | (54.6) | 334 | (52.1) | 410 | (55.9) | |
| Amphetamines/ Methamphetamines | 513 | (38.5) | 255 | (39.8) | 273 | (37.2) | |
| Dissociatives | 484 | (36.3) | 254 | (39.6) | 244 | (33.2) | |
| Benzodiazepines | 332 | (24.9) | 172 | (26.8) | 167 | (22.8) | |
| Opioids | 164 | (12.3) | 87 | (13.6) | 81 | (11.0) | |
| New Psychoactive substances | 160 | (12.0) | 86 | (13.4) | 77 | (10.5) | |
| GHB/GBL | 101 | (7.6) | 47 | (7.3) | 58 | (7.9) | |
User/Non-User refers to use of psychedelics in the specified time periods.
Unless otherwise stated, percentages refer to the respective sub-sample.
a
Refers to comparison between users and non-users,
b
percentages from total sample size of n = 1,375.